Stem Cell Therapeutic and Research Reauthorization Act of 2025
- Last Action
- 5/21/2026
Actions
- 2026-07-21Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
- 2026-07-20Motion to reconsider laid on the table Agreed to without objection.
- 2026-07-20On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- 2026-07-20Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- 2026-07-20DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
- 2026-07-20Considered under suspension of the rules. (consideration: CR H4642-4643)
- 2026-07-20Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- 2026-07-02Placed on the Union Calendar, Calendar No. 629.
- 2026-07-02Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- 2026-07-02Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- 2026-05-21Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
- 2026-05-21Committee Consideration and Mark-up Session Held
- 2026-05-13Forwarded by Subcommittee to Full Committee by Voice Vote.
- 2026-05-13Subcommittee Consideration and Mark-up Session Held
- 2025-09-04Referred to the Subcommittee on Health.
Showing 15 of 18 actions. Full history on Congress.gov.
CRS Summary
As of 2026-07-02 (07)
Stem Cell Therapeutic and Research Reauthorization Act of 2025
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Cosponsors (20)
- Doris Matsui (D-CA)
- Gus Bilirakis (R-FL)
- Chellie Pingree (D-ME)
- Claudia Tenney (R-NY)
- Kweisi Mfume (D-MD)
- Michelle Fischbach (R-MN)
- Debbie Dingell (D-MI)
- Josh Gottheimer (D-NJ)
- Robert Aderholt (R-AL)
- Nicole Malliotakis (R-NY)
- Kathy Castor (D-FL)
- Andrew Garbarino (R-NY)
- Eleanor Norton (D-DC)
- Cliff Bentz (R-OR)
- Nanette Barragán (D-CA)
- Brad Finstad (R-MN)
- Kelly Morrison (D-MN)
- Michael Lawler (R-NY)
- Eugene Vindman (D-VA)
- Brian Fitzpatrick (R-PA)
Subjects
- Biological and life sciences
- Blood and blood diseases
- Cell biology and embryology
- Health programs administration and funding
- Organ and tissue donation and transplantation
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.